NPG mice publications：

1. Glycometabolic reprogramming-induced XRCC1 lactylation confers therapeutic resistance in ALDH1A3-overexpressing glioblastoma.

2. Rapamycin increases leukemia cell sensitivity to chemotherapy by regulating mTORC1 pathway-mediated apoptosis and autophagy

3. Establishment of human acute monocytic leukemia model with systemic infiltration in NPG mice.

4. Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor.

5. Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming.

6. E2F1-mediated AUF1 upregulation promotes HCC development and enhances drug resistance via stabilization of  AKR1B10.

7. Acute toxicities of intravenous, intraperitoneal, or intratumoral injection of natural killer cells in human pancreatic adenocarcinoma-bearing mice: Randomized study.

8. Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma.

9. Docetaxel enhances the therapeutic efficacy of PSMA-specific CAR-T cells against prostate cancer models by suppressing MDSCs.

10. A plant immune protein enables broad antitumor response by rescuing microRNA deficiency.

11. Bispecific Antibody PD-L1 x CD3 Boosts the Anti-Tumor Potency of the Expanded Vγ2Vδ2 T Cells.

12. Human pluripotent stem cell-derived eosinophils reveal potent cytotoxicity against solid tumors.

13. Chemically defined and xeno-free culture condition for human extended pluripotent stem cells.

14. Chimeric Antigen Receptor-modified T Cells Repressed Solid Tumors and Their Relapse in an Established Patient-derived Colon Carcinoma Xenograft Model.

15. PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity.

16. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.

17. Engineered T lymphocytes eliminate lung metastases in models of pancreatic cancer.

18. CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells.

19. CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells.

20. miR-22 Inhibits CD34+ Cell Expansion Through Decreasing β-Catenin in Osteoblasts.

21. Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA.

F344RG rats publications：

1. Study on Preclinical Safety and Toxic Mechanism of Human Umbilical  Cord Mesenchymal Stem Cells in F344RG Rats.